story of the week
Bevacizumab Does Not Improve Overall Survival in Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
J. Clin. Oncol 2019 Jun 19;[EPub Ahead of Print], KS Tewari, RA Burger, D Enserro, BM Norquist, EM Swisher, MF Brady, MA Bookman, GF Fleming, H Huang, HD Homesley, JM Fowler, BE Greer, M Boente, SX Liang, C Ye, C Bais, LM Randall, JK Chan, JS Ferriss, RL Coleman, C Aghajanian, TJ Herzog, PJ DiSaia, LJ Copeland, RS Mannel, MJ Birrer, BJ MonkFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.